Medical Disclaimer

Semaglutide for Women (semaglutideforwomen.com) is an independent educational resource focused on the science of GLP-1 receptor agonists, with particular emphasis on sex-specific pharmacology and women’s health considerations. This site is written and maintained by Olivia Nightingale.

Not Medical Advice

Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations. The content is intended for informational and educational purposes only. No doctor-patient relationship is created between you and any contributor to this site by reading, commenting on, or otherwise engaging with our content.

Our Editorial Position on Prescriptions

We believe FDA-approved semaglutide (Ozempic®, Wegovy®, Rybelsus®), obtained through a licensed healthcare provider, is the appropriate path for individuals considering GLP-1 therapy. Pharmaceutical-grade medications manufactured under GMP conditions offer consistency, sterility, and regulatory oversight that alternatives cannot match.

We encourage readers to work with qualified healthcare providers — particularly those with expertise in obesity medicine, endocrinology, or women’s health — for any decisions about GLP-1 medications.

Research Peptides

Where this site references research-grade peptides or research peptide vendors, such content is provided for informational context only. Research peptides are sold exclusively for in-vitro laboratory research and are not approved for human consumption. We do not recommend, encourage, or endorse the purchase or use of research peptides for self-administration.

Women’s Health Considerations

Semaglutide and other GLP-1 receptor agonists carry specific considerations for women, including but not limited to:

Pregnancy and fertility: GLP-1 receptor agonists are contraindicated during pregnancy. Semaglutide should be discontinued at least 2 months before planned conception due to its extended half-life.
Menstrual cycle effects: GLP-1 medications may affect cycle regularity, flow, and ovulatory function. Increased fertility has been reported in women with PCOS.
Hormonal interactions: Estrogen modulates GLP-1 receptor sensitivity. Effects may vary across the menstrual cycle and with hormonal contraceptive use.
Bone density: Rapid weight loss from any cause can reduce bone mineral density. Women, particularly post-menopausal women, should discuss monitoring with their provider.
Thyroid considerations: GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors. Women with thyroid conditions should discuss individual risk with their endocrinologist.

These considerations are not exhaustive. Individual medical decisions should be made in consultation with a qualified healthcare provider who can evaluate your specific health profile.

Consult Your Healthcare Provider

Always consult a licensed healthcare professional before starting, stopping, or modifying any medication or supplement regimen. If you experience adverse effects from any medication, contact your healthcare provider or call emergency services immediately.

For our affiliate and vendor disclosure policies, see our Affiliate & Vendor Disclosure page.

Last updated: February 2026